Xilio Therapeutics Inc
XLO
$1.28
Closing
▲4.07%
1D
▲132.73%
YTD
Market cap
$44.13M
52 week high
$3.33
52 week low
$0.49
Volume
44,353
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$44.13M
Analysts' Rating
BUY
Price Target (Mean)
8
Total Analysts
4
P/E
Operating Margin
0.00%
Beta
Revenue Growth (Annual)
0.00%
52 week high
$3.33
52 week low
$0.49
Div. Yield
%
EPS Annual Growth
-12.86
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company, which is focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The Company has built its geographically precise solutions platform to rapidly engineer molecules, including cytokines and other biologics. Its tumor-activated, clinical-stage product candidates are XTX202, an interleukin 2 (IL-2), therapy, XTX301, an interleukin 12 (IL-12), therapy and XTX101. Its XTX101 is designed to deplete regulatory T cells when activated (unmasked) in the tumor microenvironment and improve upon the therapeutic index of existing anti-CTLA-4 therapies. Its XTX101 in an ongoing Phase I clinical trial in patients with advanced solid tumors. XTX202 is an investigational tumor-activated beta-gamma biased (non-alpha), engineered IL-2 molecule designed to potently stimulate CD8+ effector T cells and NK cells without concomitant stimulation of regulatory T cells.
